Skip to main content.
kumc.edu
Home

Sunil H. Abhyankar, MD

Sunil Abhyankar portrait
Professor, Hematologic Malignancies and Cellular Therapeutics

Professional Background

I completed my medical school from the University of Bombay followed by residency and specialized training in Pediatrics and Pediatric Hematology and Oncology from Wadia Hospital, University of Bombay and then subsequently at Downstate Medical Center in NYC. I then had the opportunity to be at the Dana Farber Cancer Institute in Boston, in BMT and focused on basic research in graft versus host disease. I have been involved with blood and marrow transplantation since 1990 and with cellular therapies from early 2000s. I currently am part of the Cellular Therapeutics team at the University of Kansas Cancer Center and oversee the cell processing lab and apheresis and also serve as the Director of the Midwest Stem cell therapy Center which has a GMP lab..

Education and Training
  • BS, Biology, Chemistry, University of Bombay, Mumbai, India
  • Internship, University of Bombay, King Edward Memorial Hospital, Mumbai, India
Professional Affiliations
  • American Society of Pediatric Hematology and Oncology , Member, 2007 - Present

Research

Overview

My research interests are in acute and chronic graft versus host disease, allogeneic transplant for malignant and non-malignant hematological disorders, infectious complications post BMT, Chimeric antigen receptor T and NK cell therapies and the use of mesenchymal and induced pluripotent cells in tissue regeneration.

Selected Publications
  • Nath Rajneesh, Seropian Stuart, Gyurkocza Boglarka, Choe Hannah, Litzow MarkR., Abboud Camille, Koshy Nebu, Stiff PatrickJ., Abhyankar SunilH., Foran James, Abedin Sameem, Chen GeorgeL, Al-Kadhimi Zaid, Kebriaei Partow, Sabloff Mitchell, Orozco JohnnieJ., Jamieson Katarzyna, Silverman Margarida, van Besien Koen, Schuster MichaelW, Law ArjunD., Spross Jennifer, Li KateL, Nagl NormanG, Vusirikala Madhuri, Nahar Akash, Desai Avinash, Tomlinson Benjamin. 2024. 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML. Transplantation and Cellular Therapy, 30 (2), S54-S55. https://doi.org/10.1016/j.jtct.2023.12.089
  • Abhyankar Sunil, Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Machado A, Thienel U, Wang J, Foss F, Apperley . 2005. A multi-institutional study of extracorporeal photoimmune therapy (ECP) with UVADEX for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (AHCT). Biology of Blood and Marrow Transplant, 11 (2), 37